# Bioavailability, Biopotency and Food Effect Study of SCD0503 Compared to Subcutaneous Regular Human Insulin

> **NCT07634770** · PHASE1 · RECRUITING · sponsor: **Sam Chun Dang Pharm. Co. Ltd.** · enrollment: 16 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **BIOLOGICAL:** oral insulin
- **OTHER:** Placebo A
- **BIOLOGICAL:** subcutaneous insulin
- **OTHER:** Placebo B

## Key facts

- **NCT ID:** NCT07634770
- **Lead sponsor:** Sam Chun Dang Pharm. Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-29
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07634770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07634770, "Bioavailability, Biopotency and Food Effect Study of SCD0503 Compared to Subcutaneous Regular Human Insulin". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07634770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*